1. Этот сайт использует файлы cookie. Продолжая пользоваться данным сайтом, Вы соглашаетесь на использование нами Ваших файлов cookie. Узнать больше.
Скрыть объявление
Немецкие анализы на боррелиоз и сопутствующие инфекции

В России появилась возможность выполнять лабораторные анализы на боррелиоз и ко-инфекции в немецкой лаборатории ArminLabs

Подробнее...

SeraSpot

Тема в разделе "Обсуждение эффективных методов диагностики", создана пользователем Niko, 11 дек 2015.

  1. Niko
    Оффлайн

    Niko Почетный форумчанин

    Сообщения:
    3.177
    Симпатии:
    3.827
    Откуда:
    ...
    Evaluation of a New Multiparametric Microspot Array for Serodiagnosis of Lyme Borreliosis

    Jana Schenk, Cornelia Doebis, Uta Küsters, Volker von Baehr
    Institut für Medizinische Diagnostik MVZ GbR, Berlin, Germany

    Background: Laboratory diagnosis of Lyme borreliosis follows a two-step algorithm, starting with a screening as- say with maximum sensitivity followed by a confirmatory assay of positive results with respect to specificity. Line immunoassays with single recombinant antigen lines are the established confirmatory test method, although result interpretation is not standardized. The present study evaluates suitability of the multiplex test SeraSpot® Anti- Borrelia IgG/IgM (SeraSpot®) as confirmatory test in serodiagnosis of Lyme disease.

    Methods: For this retrospective study, serum samples from patients with suspicion of Lyme borreliosis were ana- lyzed. For determination of specificity, blood donor samples as well as rheumatoid factor (RF), ANA, and EBV positive sera were investigated. The SeraSpot® IgG/IgM results were compared with the recomBead® Borrelia IgG/ IgM (recomBead®) test as alternative multiplex-based method.

    Results: In comparison to the recomBead® test the sensitivity of SeraSpot® was determined 95% for IgG/IgM de- tection. The analysis of blood donors revealed a specificity of ≥ 96.0% for SeraSpot® IgG/IgM and of 97.3% for re- comBead® IgG/IgM. RF positive samples tested negative by both assays (specificity of 100%). ANA and EBV anti- body positive samples resulted in specificities of ≥ 90% (SeraSpot® IgG/IgM) and ≥ 94% (recomBead® IgG/IgM) and ≥ 91% (SeraSpot® IgG/IgM) and ≥ 91% (recomBead® IgG/IgM). The intra- and interassay coefficient of varia- tion (CV) and the lot-to-lot reproducibility of the SeraSpot® assay ranged between 1 - 9% for the different Borrelia IgG and IgM antigens. Potentially interfering substances (bilirubin F, bilirubin C, hemoglobin, lipid factor, and rheumatoid factor) did not influence the SeraSpot® assays.

    Conclusions: Our evaluation data confirm that new multiplex assay generations such as SeraSpot®Anti-Borrelia IgG/IgM are reliable and robust test systems suitable for application as confirmatory tests for serodiagnosis of Lyme borreliosis.
    (Clin. Lab. 2015;61:xx-xx. DOI: 10.7754/Clin.Lab.2015.150310)

    Clinical Laboratory

    Вот наконец и данные по блоту который делает Шварцбах ArminLabs GmbH | Antibodies
     
    Irik и Libra нравится это.

Поделиться этой страницей